Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KL1333 long-term extension in primary mitochondrial disease
2025-524367-20-00Phase 2Authorised
- Sponsor
- Pharming Group
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label, single-arm trial of napazimone in Mitochondriopathy, sponsored by Pharming Group. Primary endpoints: All safety parameters and Adverse events of special interest. Planned start Jun 2026; status: authorised.
02
Drugs
napazimone
03
Conditions
Mitochondriopathy
Beyond the preview
Go deeper on 2025-524367-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524367-20-00.